Polihexanide
Active ingredient · 2 therapeutic classes
Sold as Akantior
- Drug class
- Biguanides and Amidines
- Availability
- See label
- Markets covered
- 2
- Products on record
- 2
Overview
Polihexanide is an active pharmaceutical ingredient in the Biguanides and Amidines group (D08AC). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 1 | November 28, 2025 |
| EU European Union | EMA | 1 | November 29, 2024 |
GBUnited Kingdom· MHRA
1 product
Uses
AKANTIOR is indicated for the treatment of Acanthamoeba keratitis in adults and children from 12 years of age.
How to take
EUEuropean Union· EMA
1 product
Uses
AKANTIOR is indicated for the treatment of Acanthamoeba keratitis in adults and children from 12 years of age.
How to take
Sources & citations
- [1]MHRA (UK) · PL360780007 · revised November 28, 2025
- [2]European Medicines Agency · EMEA/H/C/005858 · revised November 29, 2024
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.